Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs Starbucks Corp (SBUX) Price & Performance

Citius Pharmaceuticals IncTrade
Starbucks CorpTrade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs Starbucks Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M), while Starbucks Corp trades at $108.4 (market cap $121.59B). The key difference: Starbucks Corp is far larger — about 6076.5× Citius Pharmaceuticals Inc's market cap, and Starbucks Corp pays a 2.33% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

CTXRSBUX
Market Cap
$20.01M$121.59B
Sector
HealthConsumer Cyclical
52-Week High
$1.82$108.37
52-Week Low
$0.48$78.46
Enterprise Value
$16.23M$140.42B
Volume
7,493,833
Dividend Yield
2.33%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR is trading at $0.765, up 13.0% in the past 24 hours, with a bullish technical signal from moving averages. The company shows strong analyst support with 83% buy ratings but faces significant financial challenges including negative earnings, a -823.34% net income margin, and consecutive quarterly EPS misses. Recent news highlights expansion of LYMPHIR cancer treatment commercialization with 78% quarterly growth in new institutional accounts.

While technical indicators suggest near-term upside potential and analyst sentiment remains positive, fundamental weaknesses including substantial losses and negative cash flow from operations present significant investment risks. The company's ability to achieve profitability through its oncology drug commercialization will determine long-term shareholder value creation.

Starbucks Corp

Starbucks (SBUX) trades at $108.03, up 3.23% with strong technical momentum and bullish moving average signals. The company shows improving fundamentals with recent earnings beats and raised 2026 guidance, though valuation remains elevated at a P/E of 61.65. Recent news highlights a successful turnaround strategy under CEO Brian Niccol, with traffic recovery and margin expansion driving optimism.

The outlook remains positive with analyst consensus pointing to $113.60 price target, though high valuation and execution risks require monitoring. Key opportunities include sustained traffic growth and cost efficiency initiatives, while risks involve premium pricing sensitivity and competitive pressures in the coffee retail space.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About Starbucks Corp

Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.

Read more on SBUX